Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Bay 59-8862 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Arm 1 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Bay 59-8862 | DRUG | 75 mg/m2 of BAY 59-8862 intravenously over one hour. Treatment will be repeated once every 3 weeks and tumor measurements will be made every 2 cycles till progression, unacceptable toxicity or consent withdrawal |
Inclusion Criteria: - measurable disease as defined by the presence of at least one measurable lesion - prior immunotherapy (up to 2 regimens) or prior radiotherapy is permitted but at least 4 weeks must have elapsed prior to enter study - life expectancy of at least 12 weeks - adequate bone marrow,...
BAY59-8862 is an investigational small molecule being studied for the treatment of breast cancer, non-small-cell lung cancer, and renal cell carcinoma. It has been evaluated in Phase 2 clinical trials for these oncology indications, including taxane-resistant metastatic breast cancer and taxane-resistant non-small-cell lung cancer.
BAY59-8862 is being developed by Bayer AG, a German pharmaceutical company. Bayer AG trades on the OTC market under the ticker symbol BAYRY. The drug is an investigational small molecule in the oncology therapeutic area.
BAY59-8862 is in Phase 2 clinical development. It has completed three Phase 2 trials, one each in breast cancer, non-small-cell lung cancer, and renal cell carcinoma. The drug is investigational and has not been approved by regulatory authorities.
BAY59-8862 has completed three Phase 2 trials: NCT00044525 in taxane-resistant metastatic breast cancer with 82 patients, NCT00044538 in taxane-resistant non-small-cell lung cancer with 102 patients, and NCT00044564 in advanced renal cell carcinoma with 54 patients. All trials are completed.
BAY59-8862 is not FDA approved. It is an investigational drug that has completed Phase 2 clinical trials for breast cancer, non-small-cell lung cancer, and renal cell carcinoma. The drug remains in clinical development and has not received marketing approval.